GSK plc (NYSE:GSK) is among the The best undervalued European stocks to buy now.. On February 4, GSK plc (NYSE:GSK) announced fourth-quarter earnings that topped analyst estimates on several important metrics. Earnings per share for the quarter were $0.6989, 9.58% higher than the forecast of $0.6378. Revenue also beat forecasts, reaching $11.81 billion versus $11.36 billion, representing an upside surprise of 3.96%.
Pixabay/Public domain
Specialty drugs were a fairly promising area, with 17% growth, while oncology exceeded expectations, with sales up 43% over the same quarter last year.
GSK plc (NYSE:GSK) issued optimistic guidance for 2026, projecting sales growth of 3-5%. The company forecasts core operating profit and earnings per share will rise even faster, between 7% and 9%, implying further margin expansion. The company’s management stated that the main drivers of future growth will be oncology and respiratory medicines, as well as the expansion of portfolio assets.
GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company that researches, develops and sells medicines and vaccines for infectious diseases, HIV, respiratory conditions, cancer and immune-related disorders.
While we recognize GSK’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: Top 10 Magic Formula Stocks for 2025 and The 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. This article was originally published in Internal jumpsuit.